ID   FOLC_HUMAN              Reviewed;         587 AA.
AC   Q05932; B3KPW4; B7Z2Z3; F5H0K6; Q5JU19; Q5JU22; Q6P2P6;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 3.
DT   10-MAY-2017, entry version 170.
DE   RecName: Full=Folylpolyglutamate synthase, mitochondrial;
DE            EC=6.3.2.17;
DE   AltName: Full=Folylpoly-gamma-glutamate synthetase;
DE            Short=FPGS;
DE   AltName: Full=Tetrahydrofolylpolyglutamate synthase;
DE            Short=Tetrahydrofolate synthase;
DE   Flags: Precursor;
GN   Name=FPGS;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), AND VARIANT
RP   VAL-22.
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E.,
RA   Howe K.L., Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Ashwell R.I.S.,
RA   Babbage A.K., Babbage S., Bagguley C.L., Bailey J., Banerjee R.,
RA   Barker D.J., Barlow K.F., Bates K., Beasley H., Beasley O., Bird C.P.,
RA   Bray-Allen S., Brown A.J., Brown J.Y., Burford D., Burrill W.,
RA   Burton J., Carder C., Carter N.P., Chapman J.C., Chen Y., Clarke G.,
RA   Clark S.Y., Clee C.M., Clegg S., Collier R.E., Corby N., Crosier M.,
RA   Cummings A.T., Davies J., Dhami P., Dunn M., Dutta I., Dyer L.W.,
RA   Earthrowl M.E., Faulkner L., Fleming C.J., Frankish A.,
RA   Frankland J.A., French L., Fricker D.G., Garner P., Garnett J.,
RA   Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C.,
RA   Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M.,
RA   Lovell J., Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S.,
RA   McLay K.E., McMurray A., Milne S., Nickerson T., Nisbett J.,
RA   Nordsiek G., Pearce A.V., Peck A.I., Porter K.M., Pandian R.,
RA   Pelan S., Phillimore B., Povey S., Ramsey Y., Rand V., Scharfe M.,
RA   Sehra H.K., Shownkeen R., Sims S.K., Skuce C.D., Smith M.,
RA   Steward C.A., Swarbreck D., Sycamore N., Tester J., Thorpe A.,
RA   Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M., West A.P.,
RA   Whitehead S.L., Willey D.L., Williams S.A., Wilming L., Wray P.W.,
RA   Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S.,
RA   Rogers J., Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANTS
RP   VAL-22 AND VAL-489.
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-353, FUNCTION, CATALYTIC
RP   ACTIVITY, COFACTOR, ENZYME REGULATION, BIOPHYSICOCHEMICAL PROPERTIES,
RP   SUBSTRATE SPECIFICITY, SUBCELLULAR LOCATION, AND ALTERNATIVE SPLICING.
RC   TISSUE=Fibroblast;
RX   PubMed=8662720; DOI=10.1074/jbc.271.22.13077;
RA   Chen L., Qi H., Korenberg J., Garrow T.A., Choi Y.J., Shane B.;
RT   "Purification and properties of human cytosolic folylpoly-gamma-
RT   glutamate synthetase and organization, localization, and differential
RT   splicing of its gene.";
RL   J. Biol. Chem. 271:13077-13087(1996).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-107, ALTERNATIVE INITIATION,
RP   AND VARIANT VAL-22.
RC   TISSUE=Placenta;
RX   PubMed=7721888; DOI=10.1074/jbc.270.16.9579;
RA   Freemantle S.J., Taylor S.M., Krystal G., Moran R.G.;
RT   "Upstream organization of and multiple transcripts from the human
RT   folylpoly-gamma-glutamate synthetase gene.";
RL   J. Biol. Chem. 270:9579-9584(1995).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 20-587 (ISOFORM 1), AND CATALYTIC
RP   ACTIVITY.
RC   TISSUE=Lymphocyte;
RX   PubMed=1409616; DOI=10.1073/pnas.89.19.9151;
RA   Garrow T.A., Admon A., Shane B.;
RT   "Expression cloning of a human cDNA encoding folylpoly(gamma-
RT   glutamate) synthetase and determination of its primary structure.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:9151-9155(1992).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 102-587.
RC   TISSUE=Placenta;
RX   PubMed=8521387;
RA   Taylor S.M., Freemantle S.J., Moran R.G.;
RT   "Structural organization of the human folypoly-gamma-glutamate
RT   synthetase gene: evidence for a single genomic locus.";
RL   Cancer Res. 55:6030-6034(1995).
RN   [8]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=8408018;
RA   Osborne C.B., Lowe K.E., Shane B.;
RT   "Regulation of folate and one-carbon metabolism in mammalian cells. I.
RT   Folate metabolism in Chinese hamster ovary cells expressing
RT   Escherichia coli or human folylpoly-gamma-glutamate synthetase
RT   activity.";
RL   J. Biol. Chem. 268:21657-21664(1993).
RN   [9]
RP   FUNCTION.
RX   PubMed=8408019;
RA   Lowe K.E., Osborne C.B., Lin B.F., Kim J.S., Hsu J.C., Shane B.;
RT   "Regulation of folate and one-carbon metabolism in mammalian cells.
RT   II. Effect of folylpoly-gamma-glutamate synthetase substrate
RT   specificity and level on folate metabolism and folylpoly-gamma-
RT   glutamate specificity of metabolic cycles of one-carbon metabolism.";
RL   J. Biol. Chem. 268:21665-21673(1993).
RN   [10]
RP   CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=8408020;
RA   Lin B.F., Huang R.F., Shane B.;
RT   "Regulation of folate and one-carbon metabolism in mammalian cells.
RT   III. Role of mitochondrial folylpoly-gamma-glutamate synthetase.";
RL   J. Biol. Chem. 268:21674-21679(1993).
RN   [11]
RP   FUNCTION.
RX   PubMed=8408021;
RA   Kim J.S., Lowe K.E., Shane B.;
RT   "Regulation of folate and one-carbon metabolism in mammalian cells.
RT   IV. Role of folylpoly-gamma-glutamate synthetase in methotrexate
RT   metabolism and cytotoxicity.";
RL   J. Biol. Chem. 268:21680-21685(1993).
RN   [12]
RP   SUBCELLULAR LOCATION.
RX   PubMed=16169100; DOI=10.1016/j.bbamcr.2005.08.004;
RA   Nair J.R., McGuire J.J.;
RT   "Submitochondrial localization of the mitochondrial isoform of
RT   folylpolyglutamate synthetase in CCRF-CEM human T-lymphoblastic
RT   leukemia cells.";
RL   Biochim. Biophys. Acta 1746:38-44(2005).
RN   [13]
RP   CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND VARIANTS
RP   LEU-13; CYS-466; VAL-489 AND PHE-499.
RX   PubMed=17875718; DOI=10.1158/0008-5472.CAN-07-0156;
RA   Leil T.A., Endo C., Adjei A.A., Dy G.K., Salavaggione O.E., Reid J.R.,
RA   Ames M.M., Adjei A.A.;
RT   "Identification and characterization of genetic variation in the
RT   folylpolyglutamate synthase gene.";
RL   Cancer Res. 67:8772-8782(2007).
RN   [14]
RP   CATALYTIC ACTIVITY, AND REACTION MECHANISM.
RX   PubMed=18672898; DOI=10.1021/bi800406w;
RA   Tomsho J.W., Moran R.G., Coward J.K.;
RT   "Concentration-dependent processivity of multiple glutamate ligations
RT   catalyzed by folylpoly-gamma-glutamate synthetase.";
RL   Biochemistry 47:9040-9050(2008).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-43, CLEAVAGE OF TRANSIT
RP   PEPTIDE [LARGE SCALE ANALYSIS] AFTER SER-42, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-539, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
CC   -!- FUNCTION: Catalyzes conversion of folates to polyglutamate
CC       derivatives allowing concentration of folate compounds in the cell
CC       and the intracellular retention of these cofactors, which are
CC       important substrates for most of the folate-dependent enzymes that
CC       are involved in one-carbon transfer reactions involved in purine,
CC       pyrimidine and amino acid synthesis. Unsubstituted reduced folates
CC       are the preferred substrates. Metabolizes methotrexate (MTX) to
CC       polyglutamates. {ECO:0000269|PubMed:8408018,
CC       ECO:0000269|PubMed:8408019, ECO:0000269|PubMed:8408021,
CC       ECO:0000269|PubMed:8662720}.
CC   -!- CATALYTIC ACTIVITY: ATP + tetrahydropteroyl-(gamma-Glu)(n) + L-
CC       glutamate = ADP + phosphate + tetrahydropteroyl-(gamma-Glu)(n+1).
CC       {ECO:0000269|PubMed:1409616, ECO:0000269|PubMed:17875718,
CC       ECO:0000269|PubMed:18672898, ECO:0000269|PubMed:8408018,
CC       ECO:0000269|PubMed:8408020, ECO:0000269|PubMed:8662720}.
CC   -!- COFACTOR:
CC       Name=K(+); Xref=ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000269|PubMed:8662720};
CC       Name=NH4(+); Xref=ChEBI:CHEBI:28938;
CC         Evidence={ECO:0000269|PubMed:8662720};
CC       Note=A monovalent cation. K(+) is most effective, followed by
CC       NH4(+) and Rb(+). Na(+), Li(+) and Cs(+) are ineffective.
CC       {ECO:0000269|PubMed:8662720};
CC   -!- ENZYME REGULATION: Activated by 10 mM sodium bicarbonate.
CC       {ECO:0000269|PubMed:8662720}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=201 uM for L-glutamate (isoform 2 at 37 degrees Celsius in
CC         the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=200 uM for MgATP (isoform 2 at 37 degrees Celsius in the
CC         presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=59 uM for pteroylglutamic acid (PteGlu) (isoform 2 at 37
CC         degrees Celsius in the presence of 1 mM ATP and 2 mM L-
CC         glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=16 uM for PteGlu(2) (isoform 2 at 37 degrees Celsius in the
CC         presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=20 uM for PteGlu(3) (isoform 2 at 37 degrees Celsius in the
CC         presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=12 uM for PteGlu(4) (isoform 2 at 37 degrees Celsius in the
CC         presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=64 uM for PteGlu(5) (isoform 2 at 37 degrees Celsius in the
CC         presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=0.81 uM for H(2)PteGlu (isoform 2 at 37 degrees Celsius in
CC         the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=47 uM for H(2)PteGlu(2) (isoform 2 at 37 degrees Celsius in
CC         the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=1.6 uM for (6ambo)-tetrahydropteroylpoly-gamma-glutamate
CC         (H(4)PteGlu) (isoform 2 at 37 degrees Celsius in the presence of
CC         1 mM ATP and 2 mM L-glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=4.4 uM for (6S)-H(4)PteGlu (isoform 2 at 37 degrees Celsius
CC         in the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=3.3 uM for (6S)-H(4)PteGlu(2) (isoform 2 at 37 degrees
CC         Celsius in the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=1.4 uM for (6S)-H(4)PteGlu(3) (isoform 2 at 37 degrees
CC         Celsius in the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=1.6 uM for (6S)-H(4)PteGlu(4) (isoform 2 at 37 degrees
CC         Celsius in the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=1.4 uM for (6S)-H(4)PteGlu(5) (isoform 2 at 37 degrees
CC         Celsius in the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=3.7 uM for (6R)-10-formyl-H(4)PteGlu (isoform 2 at 37 degrees
CC         Celsius in the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=2.7 uM for (6R)-10-formyl-H(4)PteGlu(2) (isoform 2 at 37
CC         degrees Celsius in the presence of 1 mM ATP and 2 mM L-
CC         glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=105 uM for (6S)-5-formyl-H(4)PteGlu (isoform 2 at 37 degrees
CC         Celsius in the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=13 uM for (6S)-5-formyl-H(4)PteGlu(2) (isoform 2 at 37
CC         degrees Celsius in the presence of 1 mM ATP and 2 mM L-
CC         glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=48 uM for (6S)-5-methyl-H(4)PteGlu (isoform 2 at 37 degrees
CC         Celsius in the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=4.4 uM for aminopterin (isoform 2 at 37 degrees Celsius in
CC         the presence of 1 mM ATP and 2 mM L-glutamate)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=55.5 uM for methotrexate (isoform 2, PubMed:17875718, at 37
CC         degrees Celsius in the presence of 10 mM ATP and pH 8.5)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=52.6 uM for methotrexate (isoform 1, PubMed:17875718, at 37
CC         degrees Celsius in the presence of 10 mM ATP and pH 8.5)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=71 uM for methotrexate (Glu-1) (isoform 2, PubMed:8662720, at
CC         37 degrees Celsius in the presence of 1 mM ATP and 2 mM L-
CC         glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=50 uM for methotrexate (Glu-2) (isoform 2, PubMed:8662720, at
CC         37 degrees Celsius in the presence of 1 mM ATP and 2 mM L-
CC         glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=148 uM for methotrexate (Glu-3) (isoform 2, PubMed:8662720,
CC         at 37 degrees Celsius in the presence of 1 mM ATP and 2 mM L-
CC         glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=5.3 uM for 5-deazaacyclotetrahydrofolate (isoform 2, at 37
CC         degrees Celsius in the presence of 1 mM ATP and 2 mM L-
CC         glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=2.8 uM for 2-methyl-5,8-dideazaisofolate (isoform 2, at 37
CC         degrees Celsius in the presence of 1 mM ATP and 2 mM L-
CC         glutamate) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         KM=1702 uM for glutamic acid (isoform 2, PubMed:17875718, at 37
CC         degrees Celsius in the presence of 10 mM ATP and pH 8.5)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         KM=2068 uM for glutamic acid (isoform 1, PubMed:17875718, at 37
CC         degrees Celsius in the presence of 10 mM ATP and pH 8.5)
CC         {ECO:0000269|PubMed:17875718, ECO:0000269|PubMed:8662720};
CC         Vmax=0.34 umol/h/mg enzyme with methotrexate as substrate
CC         (isoform 2, PubMed:17875718, at 37 degrees Celsius in the
CC         presence of 10 mM ATP and pH 8.5) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         Vmax=0.05 umol/h/mg enzyme with methotrexate as substrate
CC         (isoform 1, PubMed:17875718, at 37 degrees Celsius in the
CC         presence of 10 mM ATP and pH 8.5) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         Vmax=1.26 umol/h/mg enzyme with glutamic acid as substrate
CC         (isoform 2, PubMed:17875718, at 37 degrees Celsius in the
CC         presence of 10 mM ATP and pH 8.5) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC         Vmax=0.25 umol/h/mg enzyme with glutamic acid as substrate
CC         (isoform 1, PubMed:17875718, at 37 degrees Celsius in the
CC         presence of 10 mM ATP and pH 8.5) {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC       pH dependence:
CC         Optimum pH is 9.6 (isoform 2). {ECO:0000269|PubMed:17875718,
CC         ECO:0000269|PubMed:8662720};
CC   -!- PATHWAY: Cofactor biosynthesis; tetrahydrofolylpolyglutamate
CC       biosynthesis.
CC   -!- SUBUNIT: Monomer.
CC   -!- SUBCELLULAR LOCATION: Isoform 1: Mitochondrion inner membrane
CC       {ECO:0000269|PubMed:16169100}. Mitochondrion matrix
CC       {ECO:0000269|PubMed:16169100, ECO:0000269|PubMed:8408020,
CC       ECO:0000269|PubMed:8662720}.
CC   -!- SUBCELLULAR LOCATION: Isoform 2: Cytoplasm
CC       {ECO:0000269|PubMed:8662720}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=4;
CC       Name=1; Synonyms=Mitochondrial;
CC         IsoId=Q05932-1; Sequence=Displayed;
CC       Name=2; Synonyms=Cytoplasmic;
CC         IsoId=Q05932-2; Sequence=VSP_018733;
CC         Note=Produced by alternative initiation at Met-43 of isoform 1.;
CC       Name=3;
CC         IsoId=Q05932-3; Sequence=VSP_018733, VSP_041959;
CC         Note=Produced by alternative splicing of isoform 1.;
CC       Name=4;
CC         IsoId=Q05932-4; Sequence=VSP_041960;
CC         Note=Produced by alternative splicing of isoform 1.;
CC   -!- SIMILARITY: Belongs to the folylpolyglutamate synthase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA35852.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK056920; BAG51826.1; -; mRNA.
DR   EMBL; AK295309; BAH12029.1; -; mRNA.
DR   EMBL; AL162586; CAI39770.1; -; Genomic_DNA.
DR   EMBL; AL162586; CAI39773.1; -; Genomic_DNA.
DR   EMBL; BC064393; AAH64393.1; -; mRNA.
DR   EMBL; AH006037; AAC13871.1; -; Genomic_DNA.
DR   EMBL; M98045; AAA35852.1; ALT_INIT; mRNA.
DR   EMBL; U14939; AAA85815.1; -; Genomic_DNA.
DR   EMBL; AH003340; AAA87568.1; -; Genomic_DNA.
DR   CCDS; CCDS35148.1; -. [Q05932-1]
DR   CCDS; CCDS35149.1; -. [Q05932-3]
DR   CCDS; CCDS75905.1; -. [Q05932-4]
DR   PIR; A46281; A46281.
DR   RefSeq; NP_001018088.1; NM_001018078.2. [Q05932-3]
DR   RefSeq; NP_001275732.1; NM_001288803.1. [Q05932-4]
DR   RefSeq; NP_004948.4; NM_004957.5. [Q05932-1]
DR   UniGene; Hs.335084; -.
DR   ProteinModelPortal; Q05932; -.
DR   BioGrid; 108639; 7.
DR   STRING; 9606.ENSP00000362344; -.
DR   BindingDB; Q05932; -.
DR   ChEMBL; CHEMBL3171; -.
DR   DrugBank; DB00142; L-Glutamic Acid.
DR   DrugBank; DB00563; Methotrexate.
DR   DrugBank; DB06813; Pralatrexate.
DR   DrugBank; DB00293; Raltitrexed.
DR   iPTMnet; Q05932; -.
DR   PhosphoSitePlus; Q05932; -.
DR   BioMuta; FPGS; -.
DR   DMDM; 1706884; -.
DR   EPD; Q05932; -.
DR   MaxQB; Q05932; -.
DR   PaxDb; Q05932; -.
DR   PeptideAtlas; Q05932; -.
DR   PRIDE; Q05932; -.
DR   DNASU; 2356; -.
DR   Ensembl; ENST00000373225; ENSP00000362322; ENSG00000136877. [Q05932-3]
DR   Ensembl; ENST00000373247; ENSP00000362344; ENSG00000136877. [Q05932-1]
DR   Ensembl; ENST00000393706; ENSP00000377309; ENSG00000136877. [Q05932-4]
DR   GeneID; 2356; -.
DR   KEGG; hsa:2356; -.
DR   UCSC; uc004bsg.3; human. [Q05932-1]
DR   CTD; 2356; -.
DR   DisGeNET; 2356; -.
DR   GeneCards; FPGS; -.
DR   HGNC; HGNC:3824; FPGS.
DR   HPA; HPA050488; -.
DR   MIM; 136510; gene+phenotype.
DR   neXtProt; NX_Q05932; -.
DR   OpenTargets; ENSG00000136877; -.
DR   PharmGKB; PA167; -.
DR   eggNOG; KOG2525; Eukaryota.
DR   eggNOG; COG0285; LUCA.
DR   GeneTree; ENSGT00390000016526; -.
DR   HOGENOM; HOG000181278; -.
DR   HOVERGEN; HBG003086; -.
DR   InParanoid; Q05932; -.
DR   KO; K01930; -.
DR   OMA; EAYAPIW; -.
DR   OrthoDB; EOG091G0DO0; -.
DR   PhylomeDB; Q05932; -.
DR   TreeFam; TF313956; -.
DR   BioCyc; MetaCyc:HS06237-MONOMER; -.
DR   Reactome; R-HSA-196757; Metabolism of folate and pterines.
DR   UniPathway; UPA00850; -.
DR   ChiTaRS; FPGS; human.
DR   GeneWiki; FPGS; -.
DR   GenomeRNAi; 2356; -.
DR   PRO; PR:Q05932; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   Bgee; ENSG00000136877; -.
DR   CleanEx; HS_FPGS; -.
DR   ExpressionAtlas; Q05932; baseline and differential.
DR   Genevisible; Q05932; HS.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:BHF-UCL.
DR   GO; GO:0005743; C:mitochondrial inner membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005759; C:mitochondrial matrix; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004326; F:tetrahydrofolylpolyglutamate synthase activity; IDA:BHF-UCL.
DR   GO; GO:0031100; P:animal organ regeneration; IEA:Ensembl.
DR   GO; GO:0007420; P:brain development; IEA:Ensembl.
DR   GO; GO:0008283; P:cell proliferation; IMP:BHF-UCL.
DR   GO; GO:0046655; P:folic acid metabolic process; TAS:Reactome.
DR   GO; GO:0006760; P:folic acid-containing compound metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006536; P:glutamate metabolic process; IDA:BHF-UCL.
DR   GO; GO:0001889; P:liver development; IEA:Ensembl.
DR   GO; GO:0006139; P:nucleobase-containing compound metabolic process; TAS:ProtInc.
DR   GO; GO:0006730; P:one-carbon metabolic process; IEA:UniProtKB-KW.
DR   GO; GO:0046901; P:tetrahydrofolylpolyglutamate biosynthetic process; IDA:BHF-UCL.
DR   Gene3D; 3.40.1190.10; -; 1.
DR   InterPro; IPR001645; Folylpolyglutamate_synth.
DR   InterPro; IPR018109; Folylpolyglutamate_synth_CS.
DR   InterPro; IPR023600; Folylpolyglutamate_synth_euk.
DR   InterPro; IPR004101; Mur_ligase_C.
DR   InterPro; IPR013221; Mur_ligase_cen.
DR   PANTHER; PTHR11136; PTHR11136; 1.
DR   PANTHER; PTHR11136:SF13; PTHR11136:SF13; 1.
DR   PIRSF; PIRSF038895; FPGS; 1.
DR   SUPFAM; SSF53244; SSF53244; 1.
DR   SUPFAM; SSF53623; SSF53623; 1.
DR   TIGRFAMs; TIGR01499; folC; 1.
DR   PROSITE; PS01011; FOLYLPOLYGLU_SYNT_1; 1.
DR   PROSITE; PS01012; FOLYLPOLYGLU_SYNT_2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative initiation; Alternative splicing;
KW   ATP-binding; Complete proteome; Cytoplasm; Ligase; Magnesium;
KW   Membrane; Metal-binding; Mitochondrion; Mitochondrion inner membrane;
KW   Nucleotide-binding; One-carbon metabolism; Phosphoprotein;
KW   Polymorphism; Reference proteome; Transit peptide.
FT   TRANSIT       1     42       Mitochondrion.
FT                                {ECO:0000244|PubMed:22814378}.
FT   CHAIN        43    587       Folylpolyglutamate synthase,
FT                                mitochondrial.
FT                                /FTId=PRO_0000010097.
FT   NP_BIND     106    109       ATP. {ECO:0000250|UniProtKB:P08192}.
FT   METAL       130    130       Magnesium 1.
FT                                {ECO:0000250|UniProtKB:P08192}.
FT   METAL       200    200       Magnesium 1.
FT                                {ECO:0000250|UniProtKB:P08192}.
FT   METAL       228    228       Magnesium 2.
FT                                {ECO:0000250|UniProtKB:P08192}.
FT   BINDING     363    363       ATP. {ECO:0000250|UniProtKB:P08192}.
FT   BINDING     377    377       ATP. {ECO:0000250|UniProtKB:P08192}.
FT   MOD_RES      43     43       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22814378}.
FT   MOD_RES     539    539       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1     42       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_018733.
FT   VAR_SEQ      43     50       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041959.
FT   VAR_SEQ     168    193       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041960.
FT   VARIANT      13     13       F -> L (in dbSNP:rs11554717).
FT                                {ECO:0000269|PubMed:17875718}.
FT                                /FTId=VAR_066016.
FT   VARIANT      22     22       I -> V (in dbSNP:rs10760502).
FT                                {ECO:0000269|PubMed:14702039,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:7721888}.
FT                                /FTId=VAR_059305.
FT   VARIANT     437    437       V -> D (in dbSNP:rs12686275).
FT                                /FTId=VAR_043929.
FT   VARIANT     466    466       R -> C (expression is reduced by 1.86-
FT                                fold; Vmax with methotrexate as substrate
FT                                is significantly reduced resulting in
FT                                significantly decreased intrinsic
FT                                clearance of methotrexate; Km of glutamic
FT                                acid is increased 3.5-fold and apparent
FT                                Vmax of it is reduced 3.4-fold; reaction
FT                                velocity at 100 nmol/L of pemetrexed is
FT                                significantly reduced and folic acid
FT                                dose-response curve is shifted to the
FT                                right which corresponds to 4.32-fold
FT                                increase in the EC(50) for folic acid;
FT                                IC(50) of methotrexate is 1.84-fold
FT                                higher and accumulation of a lower ratio
FT                                of long-chain methotrexate polyglutamates
FT                                to short-chain polyglutamates is
FT                                detected; all results are for isoform 2
FT                                variant in comparison to the wild-type of
FT                                it; dbSNP:rs35789560).
FT                                {ECO:0000269|PubMed:17875718}.
FT                                /FTId=VAR_066017.
FT   VARIANT     489    489       A -> V (in dbSNP:rs17855900).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:17875718}.
FT                                /FTId=VAR_043930.
FT   VARIANT     499    499       S -> F (expression reduced by 2.11-fold;
FT                                Vmax with methotrexate as substrate is
FT                                significantly reduced resulting in
FT                                significantly decreased intrinsic
FT                                clearance of methotrexate; apparent Vmax
FT                                for glutamic acid is reduced 5-fold;
FT                                reaction velocity at 100 nmol/L of
FT                                pemetrexed is significantly reduced and
FT                                folic acid dose-response curve is shifted
FT                                to the right which corresponds to 4.28-
FT                                fold increase in the EC(50) for folic
FT                                acid; IC(50) of methotrexate is 1.64-fold
FT                                higher and accumulation of a lower ratio
FT                                of long-chain methotrexate polyglutamates
FT                                to short-chain polyglutamates is
FT                                detected; all results are for isoform 2
FT                                variant in comparison to the wild-type of
FT                                it; dbSNP:rs200314440).
FT                                {ECO:0000269|PubMed:17875718}.
FT                                /FTId=VAR_066018.
FT   VARIANT     528    528       S -> T (in dbSNP:rs34354111).
FT                                /FTId=VAR_043931.
FT   CONFLICT    101    101       V -> A (in Ref. 1; BAG51826).
FT                                {ECO:0000305}.
SQ   SEQUENCE   587 AA;  64609 MW;  5AF81409F5F77E5C CRC64;
     MSRARSHLRA ALFLAAASAR GITTQVAARR GLSAWPVPQE PSMEYQDAVR MLNTLQTNAG
     YLEQVKRQRG DPQTQLEAME LYLARSGLQV EDLDRLNIIH VTGTKGKGST CAFTECILRS
     YGLKTGFFSS PHLVQVRERI RINGQPISPE LFTKYFWRLY HRLEETKDGS CVSMPPYFRF
     LTLMAFHVFL QEKVDLAVVE VGIGGAYDCT NIIRKPVVCG VSSLGIDHTS LLGDTVEKIA
     WQKGGIFKQG VPAFTVLQPE GPLAVLRDRA QQISCPLYLC PMLEALEEGG PPLTLGLEGE
     HQRSNAALAL QLAHCWLQRQ DRHGAGEPKA SRPGLLWQLP LAPVFQPTSH MRLGLRNTEW
     PGRTQVLRRG PLTWYLDGAH TASSAQACVR WFRQALQGRE RPSGGPEVRV LLFNATGDRD
     PAALLKLLQP CQFDYAVFCP NLTEVSSTGN ADQQNFTVTL DQVLLRCLEH QQHWNHLDEE
     QASPDLWSAP SPEPGGSASL LLAPHPPHTC SASSLVFSCI SHALQWISQG RDPIFQPPSP
     PKGLLTHPVA HSGASILREA AAIHVLVTGS LHLVGGVLKL LEPALSQ
//
